Biocomposites Acquires Artoss GmbH (NanoBone technology)

Isto Biologics Acquires NovaBone Products LLC

August 4, 2026

Healthcare Services

Isto Biologics announced the acquisition of NovaBone Products LLC, a developer and manufacturer of synthetic bone graft products, from Halma plc. The deal, supported by Keensight Capital, adds NovaBone’s bioactive glass technologies to Isto’s bone graft substitutes platform and expands its geographic reach and surgical end-market presence.

BioStem Technologies Acquires BioTissue's Surgical and Wound Care Business

January 22, 2026

Medical Devices

BioStem Technologies (OTC: BSEM) has acquired the surgical and wound care business of BioTissue Holdings, Inc. for approximately $15 million upfront, with up to $25 million of contingent milestone and royalty payments. The deal includes the Neox and Clarix product lines, a nationwide commercial sales organization and assigned GPO contracts, expanding BioStem's access into hospital inpatient and outpatient wound-care markets and adding assets that generated roughly $29 million in 2025.

Artis BioSolutions Acquires Landmark Bio

April 2, 2025

Biotechnology

Artis BioSolutions, a newly launched CDMO backed by Oak HC/FT, has acquired Landmark Bio to expand capabilities for the development and manufacturing of cell and gene therapies. Landmark Bio will continue to operate as a distinct entity from its Watertown, Massachusetts headquarters while leveraging Artis' funding and platform to scale process development, GMP manufacturing, and commercialization support.

Biocomposites Takes Minority Stake in Renovos Biologics

July 5, 2023

Biotechnology

Biocomposites has taken a minority equity stake in Renovos Biologics to support development and pre-market approval of the RENOVITE nanoclay therapeutic delivery platform. The investment will give Renovos access to Biocomposites' development expertise and global distribution network; Biocomposites CEO Michael Harris will join Renovos' board.

Fortis Life Sciences Acquires nanoComposix

July 23, 2021

Biotechnology

Fortis Life Sciences completed its acquisition of nanoComposix, a San Diego–based nanomaterials company focused on assay development, diagnostics and drug-delivery applications. The deal (closed June 2021) brings nanoComposix into the Fortis Life Sciences platform to expand its life-science reagents and contract-manufacturing capabilities and create synergies across the portfolio.

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.